Skip to main content
KPC PHARMACEUTICALS, INC. logo

KPC PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · 600422 ISIN · CNE0000015P8 LEI · 3003007ZALHXKUFMKN96 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 2,727 across all filing types
Latest filing 2017-04-27 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 600422

About KPC PHARMACEUTICALS, INC.

https://en.kpc.com.cn/

KPC Pharmaceuticals, Inc. specializes in the research, development, and manufacturing of pharmaceutical products, with a significant focus on natural and botanical medicines. The company is a global leader in the production of artemisinin-based anti-malarial treatments, including artemether and its derivatives. Its portfolio encompasses a wide range of therapeutic areas, notably cardiovascular and cerebrovascular health, where it utilizes Panax notoginseng saponins as a core component. KPC integrates traditional medicinal knowledge with modern pharmacological techniques to develop standardized botanical extracts and chemical drugs. The organization operates extensive production facilities and research centers dedicated to drug discovery and quality control. Its business activities extend to the distribution of healthcare products and the provision of medical services, aiming to provide comprehensive health solutions through innovation in natural medicine and biotechnology.

Recent filings

Filing Released Lang Actions
关于昆药集团医药商业有限公司收购楚雄州虹成药业有限公司60%股权的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the acquisition of 60% equity in a company (楚雄州虹成药业有限公司) by 昆药集团医药商业有限公司, a wholly owned subsidiary of 昆药集团股份有限公司. It includes transaction overview, parties involved, financial data, valuation reports, transaction terms, payment schedules, governance arrangements post-transaction, risk analysis, and impact on the company. The content is focused on a specific capital transaction involving acquisition and investment, with detailed financial and operational terms. There is no indication that this is a full annual or interim report, audit report, earnings release, or other types of filings. The document is not a mere announcement of a report publication but a substantive disclosure of a financing and capital transaction. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length (over 10,000 characters) and detailed content support a high confidence in this classification.
2017-04-27 Chinese
2017年第一季度报告
Interim / Quarterly Report Classification · 98% confidence The document is titled "2017 年第一季度报告" which translates to "2017 First Quarter Report." It contains detailed financial data including consolidated and parent company balance sheets, profit and loss statements, cash flow statements, and notes on financial performance for the first quarter of 2017. The report is unaudited as stated in the text. The length of the document is about 15,000 characters, indicating it is a full report rather than a brief announcement. The content includes comprehensive financial statements and analysis for a period shorter than a full fiscal year, consistent with an Interim / Quarterly Report. There is no indication that this is an annual report, audit report, or other filing types. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q1 2017
2017-04-27 Chinese
董事会关于昆药集团医药商业有限公司收购楚雄州虹成药业有限公司60%股权评估相关事宜的审核意见
Capital/Financing Update Classification · 95% confidence The document is a board opinion regarding the evaluation of an acquisition of 60% equity in another company. It discusses due diligence, evaluation methods, and fairness of the valuation. This is related to a transaction and capital investment activity. It is not a full financial report, audit report, or earnings release. It is not a regulatory filing or announcement of voting results. The content fits best under Capital/Financing Update (CAP) as it concerns acquisition and capital structure changes.
2017-04-27 Chinese
独立董事关于昆药集团医药商业有限公司收购楚雄州虹成药业有限公司60%股权评估相关事宜的独立意见
Legal Proceedings Report Classification · 85% confidence The document is an independent directors' opinion on the evaluation related to the acquisition of 60% equity in a company. It discusses the assessment of the professional capability and independence of the appraisal institution involved in the acquisition transaction. This is a specific opinion related to a transaction rather than a full report or announcement of voting results. It does not contain financial statements or earnings data, nor is it a general regulatory filing or a report publication announcement. The content aligns with a legal or regulatory update on a significant transaction, but since it is an independent opinion on an acquisition-related evaluation, it fits best under Legal Proceedings Report (LTR) as it involves regulatory compliance and due diligence in a transaction context.
2017-04-27 Chinese
八届三十次董事会决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at the 30th meeting of the 8th Board of Directors of Kunming Pharmaceutical Group Co., Ltd. It includes details about board decisions such as changes in board committee members, approval of quarterly report agenda, investment decisions, acquisitions, cooperation agreements, equipment purchases, executive reward plans, and establishment of a foreign office. The document is titled as a "Board of Directors Resolution Announcement" and contains voting results for each agenda item. It does not contain the actual quarterly report or financial statements but references the approval of the 2017 Q1 report. The document length is 3270 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document fits the category of Board/Management Information (MANG), as it announces changes and decisions made by the board rather than presenting full financial data or detailed reports.
2017-04-27 Chinese
关于收到华方科泰业绩补偿款的公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by Kunming Pharmaceutical Group Co., Ltd. regarding the receipt of a performance compensation payment related to a prior acquisition of Beijing Huafang Ketai Pharmaceutical Technology Co., Ltd. It details the background of the acquisition, the performance commitments, the audit results, and the compensation payment received. The document is short (921 characters) and focuses on a specific financial transaction related to performance compensation rather than presenting comprehensive financial data or a full report. It is an announcement of a corporate event related to capital or financing activities (performance compensation payment due to unmet profit targets). Therefore, it fits best under Capital/Financing Update (CAP).
2017-04-23 Chinese

Browse filings by year

26 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.